Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.

News

PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
10 October 2024
Open
PR: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
01 October 2024
Open
AH: Heidelberg Pharma AG Announces Updated Guidance
01 October 2024
Open
PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
23 September 2024
Open

Meet us

ADC Pharmacokinetics & Clinical Pharmacology Summit

8. - 10. Oktober

Heidelberg Pharma Virtual KOL Event on Multiple Myeloma and Updated Clinical Data

15. Oktober, 17:00 CEST/ 11:00 EDT

    Partner Information

    TitleDate
    Telix: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
    3 October 2024
    Read more
    Telix: 'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
    11 September
    Read more
    Telix: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
    3 June 2024
    Read more
    Telix: First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
    2 May 2024
    Read more